Cohen's SAC Capital Wants A Higher Bid for Pharmion (PHRM)
More News related to CELG
- Celgene Corporation to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
- More Than 200 Abstracts Evaluating Celgene Products across a Range of Indications to Be Presented at the 51st American Society of Hematology Meeting
- Celgene Corporation to Present at Two Upcoming Investor Conferences
- Celgene Corporation to Present at the Oppenheimer & Co. Inc. 20th Annual Healthcare Conference
- Celgene Corporation (CELG) Reports Q3 EPS of $0.56
More News related to PHRM
- Pharmion (PHRM) Shareholders Approve Acquisition by Celgene (CELG)
- Cohen's SAC Capital Moves Out of Pharmion (PHRM)
- Cohen's SAC Capital Wants A Higher Bid for Pharmion (PHRM)
- Cohen's SAC Capital Boosts Stake in Pharmion (PHRM) to 8.3%
- Cohen's SAC Capital Discloses 7% Stake in Merger Stock Pharmion (PHRM)
More News related to 13Ds
- Nanosphere (NSPH) Receives 510(k) from U.S. FDA to Update RVNATSP to Include Flu Cultured Clinical Isolates with H1N1 Virus
- Transcept Pharma (TSPT) to Meet with U.S. FDA To Discuss NDA Response Letter for Intermezzo
- DARA BioSciences (DARA) Says Clinical Trial on KRN5500 Achieved Its Primary Endpoint
- Nymox Pharmaceutical (NYMX) Announces Positive Clinical Data on BPH Drug NX-1207
- ARCA Biopharma (ABIO) Annouces Gencaro OK'd by U.S. FDA for Fast Track Program
In an amended 13D filing on Pharmion Corporation (Nasdaq: PHRM) after the close, Steven Cohen's SAC Capital, an 8.3% holder, disclosed a letter sent to the company saying the proposed merger with Celgene (Nasdaq: CELG) undervalues the company and they believe the merger consideration should be increased if shareholders are not given the opportunity to assess competitive data from the Phase III Dacogen EORTC study, or else the vote should be delayed to give shareholders that opportunity.
In the letter, SAC Capital said, "If the Dacogen trial fails or produces data that are clearly worse than Vidaza's survival data, we believe Pharmion would be worth $80 - $100 or more as a standalone company versus the $72 per share in stock and cash offered by Celgene."
Shares of Pharmion are currently trading at around $69.
Related Categories
13DsMergers and Acquisitions
Rumors
Stocks Mentioned
-0.42
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
